Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
about
Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Beyond the Electrocardiogram: Mutations in Cardiac Ion Channel Genes Underlie Nonarrhythmic Phenotypes.LAMP2 shines a light on cardiomyopathy in an athlete.Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?Long-term flecainide therapy in type 3 long QT syndrome.Different electrophysiological effects of the levo- and dextro-rotatory isomers of mexiletine in isolated rabbit cardiac muscle.Molecular Pathophysiology of Congenital Long QT Syndrome.Therapeutic Strategies Targeting Inherited Cardiomyopathies.Quinidine for Brugada syndrome: Panacea or poison?Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.Late sodium current associated cardiac electrophysiological and mechanical dysfunction.The congenital long QT syndrome Type 3: An update.Variants: Association With Cardiac DisordersMexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients
P2860
Q31136281-440061C6-8D0A-4572-82CD-B371024E1158Q33565907-67DD010F-2795-4DB2-B9AD-FD111A174428Q33644541-DE74A73F-00A0-4D84-8D50-08B661CC4BB7Q38856035-B91F4F61-A045-4BC3-BD11-D016B62C4875Q38878680-5E419B61-A5B5-4A14-AE29-5548533B48EEQ38947957-D2CE7135-C19B-4F18-A614-74A0940F5F83Q38997049-BB0130D8-5D86-42C8-9867-028F88D62796Q39404059-A7FCE2FD-187A-471B-BA2C-F82DA261A70CQ41992596-6C475835-F9DA-4295-9752-7524264F782DQ47135264-CB5CF537-61FB-4845-87B6-BDA19FFB2427Q47927200-44EB56D9-AED8-46EB-9684-B07A4B5661E9Q49209350-3E5DEDD7-2290-436E-BEBA-C0F01A9B65C5Q50061975-6E77F739-91B7-48DC-ACAD-7C19DA8C686EQ50176761-674D0EFD-FB11-43BD-930C-43662321032CQ58578329-02C2020A-AB91-48EC-85B8-7C25F061EBC4Q58805534-275FCB80-9BDE-4126-88D3-2BBB4F1DB2A2
P2860
Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Gene-Specific Therapy With Mex ...... With Long QT Syndrome Type 3.
@ast
Gene-Specific Therapy With Mex ...... With Long QT Syndrome Type 3.
@en
type
label
Gene-Specific Therapy With Mex ...... With Long QT Syndrome Type 3.
@ast
Gene-Specific Therapy With Mex ...... With Long QT Syndrome Type 3.
@en
prefLabel
Gene-Specific Therapy With Mex ...... With Long QT Syndrome Type 3.
@ast
Gene-Specific Therapy With Mex ...... With Long QT Syndrome Type 3.
@en
P2093
P2860
P50
P1476
Gene-Specific Therapy With Mex ...... s With Long QT Syndrome Type 3
@en
P2093
Alessandro Faragli
Mirella Memmi
Nicola Monteforte
Paola Baiardi
Raffaella Bloise
Riccardo Maragna
Susan P Etheridge
Vincenzo Bagnardi
P2860
P304
P356
10.1016/J.JACC.2015.12.033
P407
P577
2016-03-01T00:00:00Z